Neramexane

Neramexane is a drug that was under development for the treatment of Alzheimer's disease, tinnitus, and a variety of other neurological disorders. It acts as a noncompetitive antagonist at the NMDA receptor, similarly to the drug memantine, which is approved for the treatment of moderate-to-severe Alzheimer's disease.

History[edit | edit source]

Neramexane was first synthesized and studied by the German pharmaceutical company Merz Pharmaceuticals. It was in clinical trials for several years, but development was discontinued in 2008 due to unsatisfactory results.

Mechanism of action[edit | edit source]

Neramexane works by blocking the NMDA receptor, a type of glutamate receptor that is involved in memory and learning. Overactivity of this receptor is thought to play a role in the development of Alzheimer's disease and other neurological disorders.

Clinical trials[edit | edit source]

Several clinical trials were conducted to evaluate the safety and efficacy of neramexane in the treatment of Alzheimer's disease and tinnitus. However, the results were not satisfactory, and development was discontinued.

References[edit | edit source]

Neramexane Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.